Presents a translational framework linking genomic resistance signatures and primary‑metastatic phenotype discordance in HR+/HER2‑ metastatic breast cancer focusing on invasive ductal carcinoma with gastric spread.
Key Takeaways
- Five-module CDK4/6 inhibitor resistance score was developed from mutation and copy‑number events
- Metastases showed higher resistance scores and greater proliferation activity than primary tumors
- High-resistance/high-discordance tumors were enriched for PI3K-axis, chromatin-remodeling, and RB-axis events